Log In Sign up
The largest database of trusted experimental protocols

Ivis imager

Manufactured by PerkinElmer
Visit Supplier
Sourced in United States

The IVIS imager is a non-invasive, in vivo imaging system that allows for the visualization and quantification of bioluminescent and fluorescent signals in small animal models. It is designed to capture high-resolution images of light-emitting biological processes within living subjects.

Automatically generated - may contain errors

Lab products found in correlation

D luciferin, by GoldBio (3 mentions) Black 96 well plate, by PerkinElmer (1 mentions) Akalumine hcl, by Fujifilm (1 mentions) Fluorofurimazine ffz, by Promega (1 mentions) Matrigel, by Jackson ImmunoResearch (1 mentions)

Close spelling variants of this product

IVIS Spectrum optical imager IVIS Kinetic Imager IVIS Lumina XR imager IVIS 200 whole body imager Lumina II IVIS imager IVIS Spectrum small animal imager IVIS Lumina imager IVIS SpectrumCT imager Xenogen IVIS Spectrum imager IVIS Lumina III imager

12 protocols using ivis imager

1

CAR-T Cytotoxicity Assay on Tumor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
H322 cells were infected with lentivirus expression FFluc-T2A-Puro and purified. CAR-T cells were co-cultured with FFluc-expressing H322 cells at various Effector: T cell (E:T) ratios in RPMI1640 media supplemented with 5% FBS for 18 h, without exogenous cytokines. Then cells were centrifuged, washed and detected using IVIS Imager (Perkin Elmer) after adding 150 μg/ml D-luciferin (Gold Biotechnology, Cat. No. LUCNA-2G) in RPMI1640 media for 5 min. The relative viabilities of tumor cells to those at E:T = 0:1 were calculated.
Ping Y., Li F., Nan S., Zhang D., Shi X., Shan J, & Zhang Y. (2020). Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. Frontiers in Cell and Developmental Biology, 8, 803.
+ Open protocol
+ Expand
2

Lung Tumor Induction and Monitoring in GEMMs

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
We used five GEMMs in this study: (1) Kras-Lox-Stop-Lox-G12D; Rosa26-Lox-Stop-Lox-Luc (Kras); (2) Kras-Lox-Stop-Lox-G12D; LKB1 Lox/Lox; Rosa26-Lox-Stop-Lox-Luc mice (KL); (3) Kras-Lox-Stop-Lox-G12D; P53 Lox/Lox; Rosa26-Lox-Stop-Lox-Luc mice (KP); (4) Kras-Lox-Stop-Lox-G12D; LKB1 Lox/Lox; P53 Lox/Lox; Rosa26-Lox-Stop-Lox-Luc (KPL); (5) LKB1 Lox/Lox; P53 Lox/Lox; PTEN Lox/Lox; Rosa26-Lox-Stop-Lox-Luc (LPP). Lung tumours were induced by Ad5-CMV-Cre (VVC-U of Iowa-1174) or LentiCre (Kerafast) delivered intranasally as described previously37 (link). Tumour growth was routinely monitored by bioluminescence imaging using an IVIS imager (PerkinElmer). All animal experiments were approved by UCLA’s Animal Research Committee (ARC) and carried out following ARC protocols and requirements. The tumour burden endpoints (morbidity; weight loss no greater than 20%; laboured breathing; impingement of animal’s ability to ambulate, eat and drink) allowed by our Institutional Animal Care and Use Committee were not exceeded. Lung tumours from different GEMM mice were collected and snap frozen in liquid nitrogen. Snap-frozen samples were stored at −80 °C until respirometry assay and western blotting analysis.
Han M., Bushong E.A., Segawa M., Tiard A., Wong A., Brady M.R., Momcilovic M., Wolf D.M., Zhang R., Petcherski A., Madany M., Xu S., Lee J.T., Poyurovsky M.V., Olszewski K., Holloway T., Gomez A., John M.S., Dubinett S.M., Koehler C.M., Shirihai O.S., Stiles L., Lisberg A., Soatto S., Sadeghi S., Ellisman M.H, & Shackelford D.B. (2023). Spatial mapping of mitochondrial networks and bioenergetics in lung cancer. Nature, 615(7953), 712-719.
+ Open protocol
+ Expand
3

In Vivo Biodistribution of Antibody Probes

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were performed in accordance with the University of Utah Institutional Animal Care and Use Committee (IACUC). As described previously,37 (link) healthy female Nu/Nu mice (n = 5), age 5–6 weeks, were used for this study. 2 nmol (10 μM, 200 μL) of either bFab-(IR680)CHP or bFab-(IR680)CHPNB was injected into each mouse via IV tail vein injection. Mice were visualized at 0.5, 12, 24, 48, 72, 96, 120, 144, 168, 192, and 240 h postinjection using an IVIS imager (PerkinElmer) with an excitation/emission wavelength 675/720 nm and exposure time of 1 s. Fluorescence measurements were averaged at each time point and divided by the average fluorescence measurement from the 0.5 h time point, to calculate a percent remaining. Mice were sacrificed at 240 h post-injection. Organs and skeletons were collected for further analysis and scanned using the same IVIS imager.
Arlotta K.J., San B.H., Mu H.H., Yu S.M, & Owen S.C. (2020). Localization of Therapeutic Fab-CHP Conjugates to Sites of Denatured Collagen for the Treatment of Rheumatoid Arthritis. Bioconjugate chemistry, 31(8), 1960-1970.
+ Open protocol
+ Expand
4

In Vivo Bioluminescence Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
For bioluminescence imaging, mice were injected intraperitoneally with 0.25 mL 15 mg/mL D-Luciferin in sterile PBS solution in a sterile laminar airflow hood. The mouse was placed in a Plexiglas anesthetizing chamber with 2.5% isoflurane for 2–3 min. The animal was removed from the anesthetizing chamber and placed into the IVIS imager (PerkinElmer). Nose cones within the IVIS imager were used to anesthetize the mice with isoflurane. Images were acquired over a 2–5 min period. The mouse was then removed from the IVIS imager, placed back in its cage, and returned to the DLAR facility once fully recovered. IVIS was done 7 days post tumor cell injection and repeated 7 days after minipump removal.
Krishnamurthy S., Li J., Bodman A., Zhang C., Yang Y, & An J. (2019). Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 62, 207-211.
+ Open protocol
+ Expand
5

In utero electroporation of ALK fusion

Check if the same lab product or an alternative is used in the 5 most similar protocols
After confirming that the expression vector contained the right inserts, embryos of CD1 mice were injected with plasmid into the fourth ventricle and electroporated in utero at E14.5. The PPP1CB–ALK fusion plasmid was used alone or in combination with CRISPR guide RNAs against Cdkn2a. Because of the incorporated IRES-Luciferase reporter on the pT2K vector, mice with successful integration of the transgene could be assessed at postnatal day 3 using bioluminescence imaging on an IVIS imager (PerkinElmer). Mice were sacrificed upon first signs of tumor-related symptoms according to humane endpoint criteria. H&E and IHC staining was performed according to standard protocols on 3-μm sections.
Clarke M., Mackay A., Ismer B., Pickles J.C., Tatevossian R.G., Newman S., Bale T.A., Stoler I., Izquierdo E., Temelso S., Carvalho D.M., Molinari V., Burford A., Howell L., Virasami A., Fairchild A.R., Avery A., Chalker J., Kristiansen M., Haupfear K., Dalton J.D., Orisme W., Wen J., Hubank M., Kurian K.M., Rowe C., Maybury M., Crosier S., Knipstein J., Schüller U., Kordes U., Kram D.E., Snuderl M., Bridges L., Martin A.J., Doey L.J., Al-Sarraj S., Chandler C., Zebian B., Cairns C., Natrajan R., Boult J.K., Robinson S.P., Sill M., Dunkel I.J., Gilheeney S.W., Rosenblum M.K., Hughes D., Proszek P.Z., Macdonald T.J., Preusser M., Haberler C., Slavc I., Packer R., Ng H.K., Caspi S., Popović M., Kotnik B.F., Wood M.D., Baird L., Davare M.A., Solomon D.A., Olsen T.K., Brandal P., Farrell M., Cryan J.B., Capra M., Karremann M., Schittenhelm J., Schuhmann M.U., Ebinger M., Dinjens W.N., Kerl K., Hettmer S., Pietsch T., Andreiuolo F., Driever P.H., Korshunov A., Hiddingh L., Worst B.C., Sturm D., Zuckermann M., Witt O., Bloom T., Mitchell C., Miele E., Colafati G.S., Diomedi-Camassei F., Bailey S., Moore A.S., Hassall T.E., Lowis S.P., Tsoli M., Cowley M.J., Ziegler D.S., Karajannis M.A., Aquilina K., Hargrave D.R., Carceller F., Marshall L.V., von Deimling A., Kramm C.M., Pfister S.M., Sahm F., Baker S.J., Mastronuzzi A., Carai A., Vinci M., Capper D., Popov S., Ellison D.W., Jacques T.S., Jones D.T, & Jones C. (2020). Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer discovery, 10(7), 942-963.
+ Open protocol
+ Expand
6

Bioluminescence Imaging of SARS-CoV-2 Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Luminescence was detected using AkaLumine-HCl (FUJIFILM Wako Chemicals), and luciferase activity in vitro was measured by the 10-s integral analysis using an AB-2270 Luminescencer Octa (Atto) according to the manufacturer’s protocol. VeroE6/TMPRSS2 cells were seeded in a black 96-well plate (PerkinElmer) at a density of 15,000 cells per well. Serially diluted B.1.1, B.1.1-NanoLuc, or B.1.1-Akaluc were used to infect the cells. At 32 hpi, cells were washed once with PBS and imaged using an IVIS Imager (PerkinElmer) at 5 min after addition of substrate: fluorofurimazine (FFz) (3 g/mL: Promega) for NanoLuc and AkaLumine-HCl (4.3 g/mL) for Akaluc. The following conditions were used for image acquisition: open emission filter, exposure time = 3 s, binning = medium: 8, field of view = 13.2 × 13.2 cm and f/stop = 1.
For in vivo experiments, infected hamsters or mice were injected with FFz (440 nmol/g) or AkaLumine-HCl (75 nmol/g) intraperitoneally according to the indicated protocol from the previous studies11 (link),12 (link) and the luminescence images were monitored by IVIS at 1, 2, and 3 dpi. The following conditions were used for image acquisition: open emission filter, exposure time = 60 s, binning = medium: 8, field of view = 13.2 × 13.2 cm and f/stop = 1. All images were analyzed using Living Image Ver4.7.3 (PerkinElmer).
Tamura T., Ito H., Torii S., Wang L., Suzuki R., Tsujino S., Kamiyama A., Oda Y., Tsuda M., Morioka Y., Suzuki S., Shirakawa K., Sato K., Yoshimatsu K., Matsuura Y., Iwano S., Tanaka S, & Fukuhara T. (2024). Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection. iScience, 27(5), 109647.
+ Open protocol
+ Expand
7

Preclinical Evaluation of CAR-T Therapy for MM

Check if the same lab product or an alternative is used in the 5 most similar protocols
Animal protocols compliant with regulations of Washington University School of Medicine Institutional animal care and use committee. Six to ten-week old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) male or female were used in all experiments. MM.1S-CG cells were injected intraveneously (i.v.) into tail veins of mice and treated with purified CAR-T cells i.v. For BLI, mice were injected intraperitoneally with 150μg/g D-luciferin (Goldbio, Saint Louis, MO) and imaged as described (18 (link)) using an IVIS Imager (Perkin Elmer, Waltham MA) or an AMI Imager (Spectral Instruments, Tucson, AZ). Significant differences in survival were determined using Log Rank (Mantel-Cox) analysis.
O’Neal J., Ritchey J.K., Cooper M.L., Niswonger J., Sofía González L., Street E., Rettig M.P., Gladney S.W., Gehrs L., Abboud R., Prior J.L., Haas G.J., Jayasinghe R.G., Ding L., Ghobadi A., Vij R, & DiPersio J.F. (2022). CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia, 36(6), 1625-1634.
+ Open protocol
+ Expand
8

In vivo ALK Inhibitor Efficacy

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
To test the effectiveness of ALK inhibition in vivo, 6-week-old CD1 mice were intracranially allografted with 5 × 105 mouse PPP1CB–ALK tumor cells (see above) to give a more standardized latency of tumor formation and to avoid having to administer treatment to very young animals. The chosen inhibitor was lorlatinib based on the in vitro results, as well as HCl and temozolomide as vehicle control and standard of care, respectively. Dosing and treatment schedules were described previously (66 (link)). Tumor growth was monitored using BLI on an IVIS imager (PerkinElmer). The tumors were allowed to develop for two weeks before animals were stratified into three treatment groups based on their luciferase signal (rank 1, 4, 7, etc., being assigned to lorlatinib, rank 2, 5, 8, etc., to temozolomide, and rank 3, 6, 9, etc., to vehicle control). Animals were monitored daily for symptoms or abnormal behavior and weighed three times a week, and were sacrificed upon first signs of tumor-related symptoms according to humane endpoint criteria.
Clarke M., Mackay A., Ismer B., Pickles J.C., Tatevossian R.G., Newman S., Bale T.A., Stoler I., Izquierdo E., Temelso S., Carvalho D.M., Molinari V., Burford A., Howell L., Virasami A., Fairchild A.R., Avery A., Chalker J., Kristiansen M., Haupfear K., Dalton J.D., Orisme W., Wen J., Hubank M., Kurian K.M., Rowe C., Maybury M., Crosier S., Knipstein J., Schüller U., Kordes U., Kram D.E., Snuderl M., Bridges L., Martin A.J., Doey L.J., Al-Sarraj S., Chandler C., Zebian B., Cairns C., Natrajan R., Boult J.K., Robinson S.P., Sill M., Dunkel I.J., Gilheeney S.W., Rosenblum M.K., Hughes D., Proszek P.Z., Macdonald T.J., Preusser M., Haberler C., Slavc I., Packer R., Ng H.K., Caspi S., Popović M., Kotnik B.F., Wood M.D., Baird L., Davare M.A., Solomon D.A., Olsen T.K., Brandal P., Farrell M., Cryan J.B., Capra M., Karremann M., Schittenhelm J., Schuhmann M.U., Ebinger M., Dinjens W.N., Kerl K., Hettmer S., Pietsch T., Andreiuolo F., Driever P.H., Korshunov A., Hiddingh L., Worst B.C., Sturm D., Zuckermann M., Witt O., Bloom T., Mitchell C., Miele E., Colafati G.S., Diomedi-Camassei F., Bailey S., Moore A.S., Hassall T.E., Lowis S.P., Tsoli M., Cowley M.J., Ziegler D.S., Karajannis M.A., Aquilina K., Hargrave D.R., Carceller F., Marshall L.V., von Deimling A., Kramm C.M., Pfister S.M., Sahm F., Baker S.J., Mastronuzzi A., Carai A., Vinci M., Capper D., Popov S., Ellison D.W., Jacques T.S., Jones D.T, & Jones C. (2020). Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer discovery, 10(7), 942-963.
+ Open protocol
+ Expand
9

RTL Liposome Tumor Accumulation Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eight- to twelve-week-old female C57BL/6J albino mice were inoculated subcutaneously in the flank with 1 × 106 LLC cells. Tumors were allowed to grow for 7–10 days until they reached a target size of 250 mm3. A baseline whole-body ventral and lateral image was captured using an IVIS imager (PerkinElmer, Hoptkin, MA, USA). Then, animals were administered VivoTrack–labeled, SN-38-loaded RTL liposomes (100 µL) and whole-body lateral images were collected at 1, 2, 4, 6, 8, and 24 h post injection. Immediately following the 24 h image vital organs (liver, whole lung, kidneys) and tumor were collected and imaged ex vivo. Vivotrack associated fluorescence in the tumor region of the whole-body images was analyzed for each time point and compared to baseline to determine time to optimal tumor accumulation for the subsequent radiation release study. Vivotrack associated fluorescence in vital organs and tumor were used to determine relative RTL biodistribution.
Stolarz A.J., Chhetri B.P., Borrelli M.J., Jenkins S.V., Jamshidi-Parsian A., Phillips J.H., Fologea D., Gandy J, & Griffin R.J. (2022). Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy. International Journal of Molecular Sciences, 23(19), 11662.
+ Open protocol
+ Expand
10

Dinutuximab Treatment for Xenograft Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
All experiments involving animals were approved by and conducted in accordance with the policies of the MD Anderson Institutional Animal Care and Use Committee. MDA-MB-231 cells (3×106 cells/mouse) expressing GFP and firefly luciferase were suspended in 50 μL of Matrigel diluted with DMEM at a 1:1 ratio and implanted into the abdominal mammary glands of female nude mice (Foxn1null; n=10) (Jackson laboratories). Tumor volume was measured weekly with calipers. Once all mice had palpable tumors (0.3×0.3×0.3 cm), which occurred about 3 weeks after implantation, they were given dinutuximab or rituximab at 1.4 mg/kg/mouse via tail vein injection wo times a week for 7 weeks. Once the tumor volume reached 2 cm, mice were euthanized by CO2. Tumor progression was tracked by approximating the tumor volume via caliper measurements and by bioluminescence imaging with an IVIS imager (PerkinElmer) as described previously.
Ly S., Anand V., El-Dana F., Nguyen K., Cai Y., Cai S., Piwnica-Worms H., Tripathy D., Sahin A.A., Andreeff M, & Battula V.L. (2021). Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. Journal for Immunotherapy of Cancer, 9(3), e001197.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!